Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP While the Phase 2/3 XIRIUS study did not meet its primary endpoint, data indicated positive trends in several prespecified secondary endpoints, such as a clinically relevant measure of visual...